Systematic review of quadrivalent vs. nonavalent vaccine as a prophylactic treatment for cervical cancer caused by human papillomavirus (HPV)

Abstract

Introduction: Prophylactic vaccines against human papillomavirus (HPV) are considered the most effective intervention for the control of the burden of HPV-related disease. Objective: To analyze and determine if the nonavalent vaccine compared to the quadrivalent vaccine is more effective as a prophylactic method to reduce the incidence of cervical cancer caused by human papillomavirus (HPV). Methods: An electronic review of articles in which the efficacy of each type of vaccine in the population of interest was analyzed, as well as comparative studies of both types of vaccine. Results: The effectiveness of the studies was assessed according to the prevalence of cases of the different types of HPV after the application of the vaccine, immunogenicity demonstrates the creation of antibodies for the different types of HPV. On the other hand, the persistence of antibodies shows if the studies assessed their presence after a specific time (evaluated in each study) and for how long the vaccine's effectiveness was found. Conclusions: The results analyzed from randomized clinical trials have shown that both vaccines are highly effective in preventing the types of high-risk HPVs included in the vaccine (HPVs 16 and 18). Additionally, nonavalent shows clinical efficacy against types 31, 33, 45, 52, and 58. LUX MÉDICA AÑO 14, NÚMERO 42, SEPT-DIC 2019, PP 37-48.